9th International mRNA Health Conference


November 09 - 10, 2021

Currently planned as hybrid event on-site in Berlin, Germany, and online via virtual platform.
Reigster now and join us at the conference!

Past events

Conference Call & Webcast: Focus Shift to Second-Generation mRNA Technology


October 12, 2021

CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced on Tuesday, October 12, 2021 the strategic decision to focus its COVID-19 vaccine development towards the development of second-generation mRNA vaccine candidates in collaboration with GSK and to withdraw its first-generation COVID-19 vaccine candidate, CVnCoV, from the current approval process with the European Medicines Agency (EMA).

The company hosted a conference call and webcast on the same day at 03:00 p.m. CEST / 09:00 a.m. EST.

Please find the corresponding press release, presentation slides and archived webcast below.

Press Conference: Focus Shift to Second-Generation mRNA Technology (German language)


October 12, 2021

CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced on Tuesday, October 12, 2021 the strategic decision to focus its COVID-19 vaccine development towards the development of second-generation mRNA vaccine candidates in collaboration with GSK and to withdraw its first-generation COVID-19 vaccine candidate, CVnCoV, from the current approval process with the European Medicines Agency (EMA).

The company hosted a German speaking press conference on the same day at 02:00 p.m. CEST / 08:00 a.m. EST.

Please find the corresponding press release, presentation slides and archived webcast below.

Downloads

Links

CureVac to Report Second Quarter and First-Half of 2021 Financial Results and Business Updates


August 16, 2021

CureVac N.V. to report financial results and business updates for the second quarter and first-half of 2021 on Monday, August 16, 2021.

Final Analysis of Phase 2b/3 Clinical Trial for CVnCoV – Webcast & Conference Call


July 1, 2021

On Wednesday, June 30, 2021, CureVac N.V. (Nasdaq: CVAC) announced results from the final analysis of its 40,000 subject international pivotal Phase 2b/3 study (the HERALD study) of the first-generation COVID-19 vaccine candidate, CVnCoV.

The company hosted a conference call and webcast on Thursday, July 1, 2021, 2:00 p.m. CET / 8:00 a.m. EDT.

A replay of the webcast can be found under "Links".

Final Analysis of Phase 2b/3 Clinical Trial of CVnCoV – Press Conference in German Language


July 01, 2021

On Wednesday, June 30, 2021, CureVac N.V. (Nasdaq: CVAC) announced results from the final analysis of its 40,000 subject international pivotal Phase 2b/3 study (the HERALD study) of the first-generation COVID-19 vaccine candidate, CVnCoV.

The company hosted a press conference in German language on Thursday, July 1, 2021, 10:00 a.m. CEST.

The corresponding presentation slides can be found under "Downloads". An replay of the press conference can be found under "Links".

Downloads

Links

Annual General Meeting 2021


June 24, 2021

The Annual General Meeting (the “AGM”) of Shareholders of CureVac N.V. was held on Thursday, June 24, 2021, at 2:00 p.m. Central European Summer Time. The AGM was held entirely virtually, without physical attendance of shareholders or others with meeting rights. You were not be able to vote during the AGM and your proxy to vote had to be received no later than 5:59 a.m. Central European Summer Time on Tuesday, June 22, 2021.

More Information

Update on Phase 2b/3 Clinical Trial for CureVac’s First-Generation COVID-19 Vaccine candidate, CVnCoV – Webcast & Conference Call


June 17, 2021

To provide an update on Phase 2b/3 clinical trial for CureVac’s first-generation COVID-19 vaccine candidate, CVnCoV, CureVac N.V. (Nasdaq: CVAC) hosted a webcast and conference call on Thursday, June 17, 2021, at 2:00 p.m. CEST / 8:00 a.m. EST.

The corresponding press release, presentation slides and transcript can be found under “Downloads”. An archived webcast can be found under "Links".

German Hauptstadtkongress Medizin und Gesundheit 2021


June 16, 2021

Virtual Panel Discussion (German only):
Medizinischer Fortschritt „Made in Germany“: Gewollt, ermöglicht und erreichbar?

STING & TLR-Targeting Therapies Summit Digital


May 25 - 27, 2021

Virtual Event

Conference Call & Webcast: Focus Shift to Second-Generation mRNA Technology


October 12, 2021

CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced on Tuesday, October 12, 2021 the strategic decision to focus its COVID-19 vaccine development towards the development of second-generation mRNA vaccine candidates in collaboration with GSK and to withdraw its first-generation COVID-19 vaccine candidate, CVnCoV, from the current approval process with the European Medicines Agency (EMA).

The company hosted a conference call and webcast on the same day at 03:00 p.m. CEST / 09:00 a.m. EST.

Please find the corresponding press release, presentation slides and archived webcast below.

CureVac to Report Second Quarter and First-Half of 2021 Financial Results and Business Updates


August 16, 2021

CureVac N.V. to report financial results and business updates for the second quarter and first-half of 2021 on Monday, August 16, 2021.

Fourth Quarter and Full-Year 2020 Financial Results and Business Updates – Conference Call & Webcast


April 15, 2021

CureVac N.V. (Nasdaq: CVAC) reported financial results and business updates for the fourth quarter and full-year of 2020 on Thursday, April 15, 2021, at 4:00 p.m. CET / 10:00 a.m. EST.

Please find the corresponding press release, presentation slides, transcript as well as the archived webcast below.

Third Quarter and First 9 Months 2020 Financial Results and Business Updates – Conference Call & Webcast


November 30, 2020

CureVac N.V. (Nasdaq: CVAC) announced financial results and business updates for the third quarter and first nine months of 2020 on Monday, November 30, 2020. The company hosted a conference call and webcast on the same day at 4:00 p.m. CET / 10:00 a.m. EST.

Please find the corresponding press release, presentation slides, transcript and archived webcast below.

Berenberg Conference USA 2021


May 18 - 20, 2021

Virtual Event

Kempen Life Sciences Conference 2021


April 28, 2021

Virtual Event

Fourth Quarter and Full-Year 2020 Financial Results and Business Updates – Conference Call & Webcast


April 15, 2021

CureVac N.V. (Nasdaq: CVAC) reported financial results and business updates for the fourth quarter and full-year of 2020 on Thursday, April 15, 2021, at 4:00 p.m. CET / 10:00 a.m. EST.

Please find the corresponding press release, presentation slides, transcript as well as the archived webcast below.

Credit Suisse 2021 London Global Healthcare Conference


March 2, 2021

Virtual Event
Fireside Chat: 12:00 p.m. GMT / 7:00 a.m. EST

Leerink 10th Annual Global Healthcare Conference


February 24, 2021

Virtual Event
Presentation: 8:00 a.m. EST

Downloads

Management attending JP Morgan 39th Annual Healthcare Conference


January 11 - 14, 2021

For meeting inquiries please contact investors@curevac.com.

Berenberg European Conference 2020


December 2, 2020

Online

Third Quarter and First 9 Months 2020 Financial Results and Business Updates – Conference Call & Webcast


November 30, 2020

CureVac N.V. (Nasdaq: CVAC) announced financial results and business updates for the third quarter and first nine months of 2020 on Monday, November 30, 2020. The company hosted a conference call and webcast on the same day at 4:00 p.m. CET / 10:00 a.m. EST.

Please find the corresponding press release, presentation slides, transcript and archived webcast below.

Positive Interim Phase 1 Data of CureVac’s COVID-19 Vaccine Candidate, CVnCoV – Conference Call & Webcast


November 10, 2020

The press release, presentation and transcript can be downloaded below, the archived webcast is available through the following link.

ACT 2020 Annual Meeting


November 15–18, 2020

Austin, Texas, USA

Berenberg US CEO Conference 2020


November 13, 2020

Online

SITC 2020


November 10–14, 2020

Online

8th International mRNA Health Conference


November 9–10, 2020

Online

ESMO Congress 2020


September 18–22, 2020

Madrid, Spain

CICON 2020


September 14–17, 2020

New York, USA

Conference Call “Strategic Partnerships to Deliver CureVac’s COVID-19 Ambition”


February 5, 2021

CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), hosted a conference call and webcast on Friday February 5, 2021 at 4:00 p.m. CET / 10:00 a.m. EST.

Please find the corresponding press release, presentation slides, transcript and archived webcast below.

ASCO Annual Meeting


May 29 – Juni 2, 2020

Chicago, USA

CIMT 2020 Annual Meeting


May 5–7, 2020

Mainz, Germany

AACR Annual Meeting 2020


April 24–29, 2020

San Diego, California, USA

World Vaccine Congress 2020


April 6–9, 2020

Washington, D.C., USA

SOT 2020


March 15–19, 2020

Anaheim, California, USA

30th Annual Healthcare Conference


March 17–18, 2020

New York, USA

IABS 65th Anniversary Meeting


February 26–28, 2020

Lyon, Frankreich

J.P. Morgan Health Care Investor Conference


January 13–17, 2020

San Francisco, USA

Piper Jaffray 31st Annual Healthcare Conference


December 3–5, 2019

New York, USA

Tides Europe 2019


November 12–15, 2019

Amsterdam, Netherlands

7th International mRNA Health Conference


November 11–12, 2019

Berlin, Germany

SITC


November 6–10, 2019

Washington, D.C., USA

World Vaccine Congress


Oktober 28–31, 2019

Barcelona, Spain

ESMO


September 27 – October 1, 2019

Barcelona, Spain

TIDES


May 20–23, 2019

San Diego, USA

3rd Drug Discovery Nexus Summit


May 22–23, 2019

Munich, Germany

AACR Annual Meeting 2019


March 31 – April 3, 2019

Atlanta, USA

Leerink 8th Annual Global Healthcare Conference


February 27 – March 1, 2019

New York, USA

AsiaTIDES


February 26–28, 2019

Tokyo, Japan

SMi RNA Therapeutics Conference 2019


February 20–21, 2019

London, United Kingdom